oncology anti cancer medicine

Zupanib Tablets (Pazopanib Tablets) – Product Description Zupanib Tablets contain Pazopanib, a prescription targeted anti-cancer medicine used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). It belongs to the tyrosine kinase inhibitor (TKI) class and works by blocking multiple enzymes involved in tumor growth and the formation of new blood vessels (angiogenesis), helping slow the progression of cancer. Zupanib is taken orally once daily, usually on an empty stomach, exactly as prescribed by the treating oncologist. It may be used as a single-agent therapy depending on the patient's diagnosis and treatment plan. Active Ingredient Pazopanib Dosage Form Oral Tablets Therapeutic Indications Advanced Renal Cell Carcinoma (Kidney Cancer) Advanced Soft Tissue Sarcoma (STS) Other approved oncology indications as determined by the treating oncologist How It Works Pazopanib inhibits multiple tyrosine kinase receptors, including VEGFR, PDGFR, and c-KIT, reducing the formation of new blood vessels that supply tumors with oxygen and nutrients. This helps inhibit tumor growth and spread. Key Features Targeted therapy for advanced kidney cancer and soft tissue sarcoma Multi-targeted kinase inhibitor with anti-angiogenic activity Convenient once-daily oral tablet May help slow disease progression in eligible patients Manufactured according to stringent pharmaceutical quality standards Storage Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children. Note: Zupanib Tablets (Pazopanib) are prescription-only medicines and should be used only under the supervision of a qualified oncologist. Regular monitoring of liver function, blood pressure, thyroid function, and overall clinical status is recommended during treatment.

Zortemib (Bortezomib Injection) – Product Description Zortemib contains Bortezomib, a prescription targeted anti-cancer medicine used for the treatment of multiple myeloma and mantle cell lymphoma (MCL). It belongs to the proteasome inhibitor class of medicines and works by blocking the 26S proteasome, causing the accumulation of damaged proteins inside cancer cells. This disruption leads to cancer cell death and helps slow the progression of the disease. Zortemib is administered by qualified healthcare professionals as an intravenous (IV) or subcutaneous (SC) injection. It may be used alone or in combination with other anti-cancer medicines depending on the patient's diagnosis, treatment stage, and clinical condition. Active Ingredient Bortezomib Dosage Form Sterile Injection (Intravenous or Subcutaneous) Therapeutic Indications Multiple Myeloma Mantle Cell Lymphoma (MCL) Other approved hematologic malignancies as determined by the treating oncologist How It Works Bortezomib selectively inhibits the 26S proteasome, preventing the breakdown of proteins within cancer cells. This causes cellular stress, disrupts normal cell function, and triggers programmed cancer cell death (apoptosis), helping to control tumor growth. Key Features Targeted therapy for multiple myeloma and mantle cell lymphoma Proteasome inhibitor with a well-established role in hematologic oncology Can be administered by intravenous or subcutaneous injection May be used as monotherapy or in combination treatment regimens Manufactured according to stringent pharmaceutical quality standards Storage Store according to the manufacturer's recommendations. Protect from moisture, excessive heat, and direct light. Keep out of reach of children. Note: Zortemib (Bortezomib Injection) is a prescription-only medicine and should be administered only under the supervision of a qualified oncologist. Regular monitoring of blood counts, liver function, kidney function, and neurological status is recommended during treatment.

Zolon (Oxaliplatin Injection) – Product Description Zolon contains Oxaliplatin, a prescription anti-cancer (chemotherapy) medicine used primarily for the treatment of colorectal cancer, including advanced and metastatic colon and rectal cancer. It belongs to the platinum-based chemotherapy class and works by damaging the DNA of cancer cells, preventing them from growing and dividing, which ultimately leads to cancer cell death. Zolon is administered as an intravenous (IV) infusion by qualified healthcare professionals. It is commonly used in combination with other chemotherapy medicines, such as 5-Fluorouracil (5-FU) and Leucovorin, as part of standard treatment regimens for colorectal cancer. Active Ingredient Oxaliplatin Dosage Form Sterile Injection for Intravenous (IV) Infusion Therapeutic Indications Colorectal Cancer Advanced Colon Cancer Metastatic Colorectal Cancer Rectal Cancer Other oncology indications as determined by the treating oncologist How It Works Oxaliplatin forms DNA cross-links within cancer cells, preventing DNA replication and repair. This disrupts cell division and triggers the death of rapidly growing cancer cells, helping to slow disease progression. Key Features Platinum-based chemotherapy for colorectal cancer Proven component of standard combination chemotherapy regimens Administered under specialist medical supervision Suitable for use in hospital and oncology clinic settings Manufactured according to stringent pharmaceutical quality standards Storage Store according to the manufacturer's recommendations. Protect from excessive heat and light. Keep out of reach of children. Tags Oxaliplatin Injection, Zolon Injection, Oxaliplatin IV Infusion, Colorectal Cancer Treatment, Colon Cancer Chemotherapy, Rectal Cancer Medicine, Platinum-Based Chemotherapy, Anti-Cancer Injection, Oncology Medicine, Metastatic Colorectal Cancer, Chemotherapy Drug, Generic Oxaliplatin, Cancer Treatment Injection, Hospital Oncology Medicine, Pharmaceutical Export India

Zixib Tablet (Axitinib Tablets) – Product Description Zixib Tablet contains Axitinib, a targeted anti-cancer medicine used primarily for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It belongs to the tyrosine kinase inhibitor (TKI) class of medicines and works by blocking vascular endothelial growth factor (VEGF) receptors, helping to reduce the blood supply that tumors need to grow and spread. Zixib is prescribed by oncologists for patients with advanced kidney cancer and may be used after prior systemic therapy or according to current treatment guidelines. The tablets are taken orally, with or without food, exactly as directed by the treating physician. Active Ingredient Axitinib Dosage Form Oral Tablets Therapeutic Indications Advanced Renal Cell Carcinoma (RCC) Advanced Kidney Cancer Other approved oncology indications as determined by the treating oncologist How It Works Axitinib selectively inhibits VEGF receptors (VEGFR-1, VEGFR-2, and VEGFR-3), preventing the formation of new blood vessels that supply nutrients and oxygen to tumors. This helps slow tumor growth and may reduce the spread of cancer. Key Features Targeted therapy for advanced kidney cancer Oral tablet for convenient administration Selective VEGF receptor inhibitor May be used alone or in combination with other oncology treatments Manufactured according to stringent pharmaceutical quality standards Storage Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children. Note: Zixib Tablet (Axitinib) is a prescription-only medicine and should be used only under the supervision of a qualified oncologist. Regular monitoring of blood pressure, liver function, thyroid function, and other clinical parameters is recommended during treatmenT.

Zitomycin (Mitomycin Injection) – Product Description Zitomycin contains Mitomycin, a prescription anti-cancer (chemotherapy) medicine used in the treatment of various solid tumors, including gastric (stomach) cancer, pancreatic cancer, and bladder cancer. It belongs to the antitumor antibiotic class of chemotherapy agents and works by preventing cancer cells from growing and multiplying through DNA cross-linking, ultimately leading to cancer cell death. Mitomycin is administered by qualified healthcare professionals as an intravenous (IV) injection or, for certain bladder cancers, as intravesical therapy directly into the bladder. It may be used alone or in combination with other chemotherapy medicines depending on the patient's condition and treatment protocol. Active Ingredient Mitomycin Dosage Form Sterile Injection Therapeutic Indications Gastric (Stomach) Cancer Pancreatic Cancer Superficial Bladder Cancer (Intravesical Therapy) Other cancers as recommended by an oncologist How It Works Mitomycin acts by forming DNA cross-links, which prevent cancer cells from replicating and repairing their DNA. This inhibits cell division and promotes the destruction of rapidly growing cancer cells. Key Features Broad-spectrum chemotherapy agent Effective in selected gastrointestinal and bladder cancers Suitable for use as monotherapy or in combination chemotherapy Administered under specialist medical supervision Manufactured according to stringent pharmaceutical quality standards Storage Store as directed by the manufacturer. Protect from light and excessive heat. Keep out of reach of children. Note: Zitomycin (Mitomycin Injection) is a prescription-only chemotherapy medicine and should only be administered by qualified healthcare professionals experienced in oncology. Regular monitoring of blood counts, kidney function, and overall health is essential during treatment.

Zinotecan (Irinotecan Injection) – Product Description Zinotecan contains Irinotecan, a prescription anti-cancer (chemotherapy) medicine used to treat advanced or metastatic colorectal cancer and certain other cancers as recommended by an oncologist. It belongs to the topoisomerase I inhibitor class of chemotherapy drugs and works by interfering with the DNA replication process in rapidly dividing cancer cells, helping to slow or stop their growth. Zinotecan is administered as an intravenous (IV) infusion by trained healthcare professionals, either alone or in combination with other chemotherapy medicines such as 5-Fluorouracil (5-FU) and Leucovorin. Treatment schedules and dosage are determined by the patient's condition, body surface area, and overall treatment plan. Active Ingredient Irinotecan Hydrochloride Dosage Form Sterile Injection for Intravenous (IV) Infusion Therapeutic Indications Metastatic Colorectal Cancer Advanced Colorectal Cancer Other solid tumors, as determined by the treating oncologist How It Works Irinotecan inhibits the topoisomerase I enzyme, preventing cancer cells from repairing damaged DNA during cell division. This results in cancer cell death and helps reduce tumor growth. Key Features Effective chemotherapy for colorectal cancer Can be used as monotherapy or combination therapy Administered under medical supervision Manufactured according to stringent pharmaceutical quality standards Intended for hospital and oncology clinic use Storage Store according to the manufacturer's recommendations. Protect from excessive heat and light. Keep out of reach of children. Note: Zinotecan (Irinotecan Injection) is a prescription-only chemotherapy medicine and should be administered only by qualified healthcare professionals experienced in cancer treatment. Regular monitoring of blood counts and overall health is required throughout therapy.